MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

MariTide only needs to be taken once a month, and it's helped people lose up to 20% of their weight. Shares of this biotech are priced at a much lower premium than top GLP-1 drugmaker Eli Lilly.

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Leading drugmaker Amgen could ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. " ...

But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key ...